Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Declaration

This exercise is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.


Activity Description

Real-world outcomes of patients with retinal diseases treated with intravitreal anti-vascular endothelial growth factor (VEGF) therapies are often suboptimal when compared to the results demonstrated in pinnacle clinical studies. The discrepancies in outcomes have in part been attributed to individuals receiving fewer than the particular recommended number of anti-VEGF injections, as well as sufferers discontinuing therapy due to treatment burden associated with frequent dosing schedules. New imaging techniques that allow for better monitoring associated with therapy response, along with the refinement of treatment protocols that will extend the interval between treatment dosing, have the potential to reduce therapy burden while providing optimal visual results. In this webinar series that represents the particular “Best of” the Real World Retina meeting, experts in the field will provide guidance on the management of neovascular age-related macular degeneration (nAMD) and retinal vein occlusion (RVO). Topics covered include utilizing recent advances inside imaging to monitor treatment reaction in patients with retinal diseases, identification of baseline factors that will help predict anti-VEGF treatment outcomes, and evaluation of anti-VEGF treatment outcomes within clinical practice.


Target Audience

The intended audience for this activity is retina specialists, ophthalmologists, and other health care professionals involved in the management associated with patients with retinal diseases.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the particular evidence for anti-VEGF therapy outcomes in age-related macular degeneration plus retinal vein occlusion in clinical exercise.
  • Identify prognostic indicators with regard to predicting anti-VEGF therapy final results in individuals with age-related macular degeneration.
  • Identify relevant patient primary factors regarding predicting anti-VEGF therapy outcomes in sufferers with retinal vein occlusion.
  • Assess the applicability of current advances inside imaging intended for monitoring treatment response in patients along with age-related macular degeneration and retinal vein occlusion.


Activity Chair

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Movie director of Fellowship
Sierra Eye Associates
Clinical Associate Teacher
College of Nevada
Reno, NV


Faculty

Caroline R. Baumal, MD, FASRS
Professor of Ophthalmology
Tufts Medicine
New England Eye Center
Boston, MA

Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin Hospitals
Stuart, FL
Teacher of Ophthalmology, Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Yasha Modi, MD
Associate Professor of Ophthalmology
New York University or college
New York, NY

Christina Y. Weng, MD, MBA
Professor associated with Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Baylor University of Medication
Houston, TX


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education will be accredited by the Certification Council to get Continuing Healthcare Education (ACCME) to provide continuing healthcare education pertaining to physicians.


Credit Designation

Vindico Medical Education designates this enduring material meant for a maximum of 2. 0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the particular learner in order to satisfy the Lifelong Studying and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner conclusion information to ACCME for the purpose of granting credit score.

Upon successful completion, learners who opt-in by providing their ABO ID plus DOB (MM/DD) will earn Continuing Accreditation credits equivalent to the amount of CME credits claimed for that activity.

This particular enduring material is approved for 1 year from the particular date associated with original release, December 30, 2022 in order to December 29, 2023.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide just one (1) correct solution for each question. The satisfactory score is defined as answering 6 of the 9 posttest questions correctly. Upon receipt of the particular completed materials, if a satisfactory score on the posttest is achieved, Vindico Healthcare Education will issue an AMA PRA Category 1 Credit(s) ™ certificate.


Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals inside a position to control the content material of a continuing education exercise, including faculty, planners, reviewers, or others, are required to disclose all related financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement from the action.

Exercise Chairs and Faculty report the following appropriate financial relationship(s)

Caroline R. Baumal, MD, FASRS
Consultant: Genentech, Novartis, Regeneron, Zeiss

Arshad M. Khanani, MD, MOTHER
Specialist: 4DMT, Adverum, Alimera, Allergan, Apellis, AsclepiX, Aviceda, Bausch + Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, Gemini, Genentech, Glaukos, Graybug, Gyroscope, Iveric Biography, Janssen, Kato, Kodiak, Novartis, Oculis, Opthea, Oxurion, Regeneron, Retrotope, Regenxbio, RevOpsis, Roche, Théa, Unity Bio
Speaker Contracted simply by Ineligible Company: Allergan, Genentech, Novartis
Independent Research Contractor: 4DMT, Adverum, Apellis, AsclepiX, Chengdu Kanghong, Gemini, Genentech, Graybug, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Biography, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxurion, Regenxbio, Roche, Unity Bio
Individual Stocks and Stock Options: Retrotope

Yasha Modi, MD
Advisor : Alcon, Alimera, Allergan, Genentech, Iveric Bio, Théa, Zeiss

Carl Deb. Regillo, MD, FACS
Consultant: 4DMT, Adverum, Aldeyra, Allergan Annexon, Apellis, Aviceda, Chengdu Kanghong, Clearside, EyePoint, Genentech, Graybug, Iveric Biography, Kodiak, Lineage, NGM Bio, Notal Vision, Novartis, Ocugen, Regenxbio, Stealth Bio, Théa
Independent Study Contractor: Adverum, Alderya, Allergan, Annexon, Apellis, Astellas, Chengdu Kanghong, Clearside, EyePoint, Genentech, Graybug, Iveric Bio, Kodiak, Lineage, NGM Bio, Novartis, Opthea, Regeneron, Regenxbio

Rishi G. Singh, MD
Expert: Alcon, Apellis, AsclepiX, Bausch + Lomb, Genentech, Gyroscope, Iveric, Novartis, Regeneron

Christina Y. Weng, MD, MBA
Consultant : Alcon, Alimera, Allergan/AbbVie, DORC, Genentech, Novartis, Opthea, Regeneron, Regenxbio
Independent Research Service provider : AGTC, DRCR Retina Network

Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA,
RPVI, CHCP

No relevant monetary relationships to disclose.

Vindico Medical Education staff statement the following relevant economic relationship(s)

No relevant financial relationships in order to disclose.

Signed disclosures are on file at Vindico Healthcare Education, Office of Medical Affairs plus Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical schooling activity may contain references to unlabeled uses of US Food and  Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the particular United States.   The particular faculty members have been made aware of their obligation to disclose such usage. Almost all activity individuals will become informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Schooling, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed within the USA. © 2022 Vindico Healthcare Education. Just about all rights reserved. No part of this particular publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and learning continuing medical education activities does not really necessarily reflect the views and opinions of Vindico Medical Training. Neither Vindico Medical Education nor the particular faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may talk about the use of components and/or items that have not yet already been approved by the US Food and Drug Administration. All readers and continuing education participants ought to verify all information before treating patients or even utilizing any product.


CME Questions?

Contact us at [email protected] com

Leave a Reply

Your email address will not be published. Required fields are marked *